“Therapeutic Targeting of Mirnas As Potential Therapy for Alzheimer’s Disease”
Alzheimer's disease has always been an unpleasant burden for many people aged over 85 or even less and it has been supposedly harder to encounter for the families of the patients and those around them. Considering both the agony and the costs dedicated for this disease, it has imposed a high morbidity rate to all societies. Alzheimer’s Disease is mainly caused by amyloid aggregation in the brain, mostly in the temporal and parietal lobes; and formation of neurofibrillary tangles which all lead to cortex atrophy and presentation of memory loss and failure in cognitive acts. The specific type of amyloid protein responsible for Alzheimer’s Disease progression is amyloid-beta, produced by the enzyme beta secretase. While the physiological role of this enzyme is still under debate, a decrease in its production may lead to a relative decrease in the severity of Alzheimer’s Diseasepresentations in a patient. MicroRNAs, on the other hand, are well-known types of RNAs which moderate gene expression. They may also be used as a therapeutic target to inhibit the expression of the gene responsible for beta secretase enzyme production and consequently decrease the unpleasant symptoms of Alzheimer’s Disease. In this review, possible therapeutic acts and aspects of Alzheimer’s Diseaseare explained, which may be considered for further research activities.